Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. | Hsieh et al. Annals of General Psychiatry 2010 9 35 http content 9 1 35 ANNALS OF GENERAL PSYCHIATRY PRIMARY RESEARCH Open Access A 64-week multicenter open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting Ming-Hong Hsieh1 2 Wei-Wen Lin2 3 Shao-Tsu Chen4 Kao-Ching Chen5 Kuang-Peng Chen6 Nan-Ying Chiu7 Chao Huang8 Ching-Jui Chang9 Cheng-Hsiu Lin10 Te-Jen Lai1 Abstract Objective To evaluate the overall long-term effectiveness of aripiprazole in patients with schizophrenia in a general psychiatric practice setting in Taiwan. Methods This was a prospective open-label multicenter post-market surveillance study in Taiwanese patients with a Diagnostic and Statistical Manual of Mental Disorders Fourth Edition DSM-IV diagnosis of schizophrenia or schizoaffective disorder requiring a switch in antipsychotic medication because current medication was not well tolerated and or clinical symptoms were not well controlled. Eligible patients were titrated to aripiprazole 5-30 mg day over a 12-week switching phase during which their previous medication was discontinued. Patients could then enter a 52-week long-term treatment phase. Aripiprazole was flexibly dosed 5-30 mg day at the discretion of the treating physicians. Efficacy was assessed using the Clinical Global Impression scale Improvement CGI-I score the Clinical Global Impression scale Severity CGI-S score The Brief Psychiatry Rating Scale BPRS and the Quality of Life QOL scale as well as Preference of Medicine POM ratings by patients and caregivers. Safety and tolerability were also assessed. Results A total of 245 patients were enrolled and switched from their prior antipsychotic medications and 153 patients entered the 52-week extension phase. In all 79 patients completed the study. At week 64 the mean CGI-I score was and of patients who showed response. .
